Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

vernal keratoconjunctivitis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

vernal keratoconjunctivitis

MONDO:0019085

Also known as:Spring catarrhVernal KeratonconjunctivitisVKC

Find Clinical TrialsTrials

Overview

Vernal keratoconjunctivitis (VKC) is a chronic, severe allergy that affectsthe surfaces of the eyes. It most commonly occurs in boys living in warm, dry climates. Attacks associated with VKC are common in the spring (hence the name 'vernal') and summer but often reoccur in the winter. Signs and symptoms usually begin before 10 years of age and may include hard, cobblestone-like bumps (papillae) on the upper eyelid; sensitivity to light; redness; sticky mucus discharge; andinvoluntary blinking or spasms of the eyelid (blepharospasm).The condition usually subsides at the onset of puberty. It is caused by ahypersensitivity (allergic reaction)to airborne-allergens. Management focuses on preventing 'flare ups' and relieving the symptoms of the condition.

Treatments5 FDA approved

Clinical Trials5 registered · 2 recruiting

Diagnosis

Biomarker and diagnostic research for vernal keratoconjunctivitis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for vernal keratoconjunctivitis, including CYCLOSPORINE (VERKAZIA, approved 2021). An additional 5 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: 1-5 in 10,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

5 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 1 PHASE3, 1 PHASE2, 1 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06913790](https://clinicaltrials.gov/study/NCT06913790)

Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 7:13 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:70476

GARD

Genetic and Rare Diseases Info Center

GARD:7854

Questions for Your Care Team

→What are the benefits and potential side effects of VERKAZIA for managing vernal keratoconjunctivitis?
→Are any of the 5 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
gleceparin	gleceparin	NexEos Diagnostics Inc. (dba NexEos Bio)	2026	—	Designated
Tacrolimus	Tacrolimus	CN2 Therapeutics, Inc.	2020	—	Designated
Alomide Ophthalmic Solution	Lodoxamide tromethamine	Alcon Laboratories, Inc.	1991	2000	Designated (drug approved for other indication)
Levocabastine HCl ophthalmic suspension 0.05%	Levocabastine HCl ophthalmic suspension 0.05%	Iolab Pharmaceuticals	1988	—	Withdrawn
Opticrom 4% ophthalmic solution	Cromolyn sodium 4% ophthalmic solution	Fisons Corporation	1985	1991	Designated (drug approved for other indication)

Research Type	Count	% of Total
Research summaries	31	33%
Disease patterns and progression	23	24%
Patient case studies	16	17%
Clinical study results	12	13%
Laboratory research	5	5%
Testing and diagnosis research	4	4%
Other research	2	2%
New treatment approaches	1	1%

Kisho

vernal keratoconjunctivitis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

A red-eye presentation concerning for vernal keratoconjunctivitis: a case report.

vernal keratoconjunctivitis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

A red-eye presentation concerning for vernal keratoconjunctivitis: a case report.